Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Depreciation & Amortization - Total: 2021-2024

Historic Depreciation & Amortization - Total for Addex Therapeutics (ADXN) over the last 4 years, with Dec 2024 value amounting to -$207,275.

  • Addex Therapeutics' Depreciation & Amortization - Total fell 72.07% to $75,159 in Q4 2024 from the same period last year, while for Dec 2024 it was -$263,799, marking a year-over-year decrease of 2167.88%. This contributed to the annual value of -$207,275 for FY2024, which is 1684.05% down from last year.
  • Per Addex Therapeutics' latest filing, its Depreciation & Amortization - Total stood at -$207,275 for FY2024, which was down 1,684.05% from $13,085 recorded in FY2023.
  • Over the past 5 years, Addex Therapeutics' Depreciation & Amortization - Total peaked at $13,085 during FY2023, and registered a low of -$305,651 during FY2022.
  • For the 3-year period, Addex Therapeutics' Depreciation & Amortization - Total averaged around -$166,614, with its median value being -$207,275 (2024).
  • As far as peak fluctuations go, Addex Therapeutics' Depreciation & Amortization - Total surged by 104.28% in 2023, and later slumped by 1,684.05% in 2024.
  • Addex Therapeutics' Depreciation & Amortization - Total (Yearly) stood at -$29,764 in 2021, then plummeted by 926.91% to -$305,651 in 2022, then soared by 104.28% to $13,085 in 2023, then crashed by 1,684.05% to -$207,275 in 2024.